L
Lifordi Immunotherapeutics
Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) to develop treatments for autoimmune and inflammatory disorders
About Lifordi Immunotherapeutics
Lifordi Immunotherapeutics is a pioneering biotechnology company focused on developing targeted antibody drug conjugates (ADCs) to treat autoimmune and inflammatory disorders. Leveraging the success of ADCs in oncology, Lifordi aims to revolutionize the treatment landscape for these conditions by targeting myeloid and lymphoid cells using a highly internalized cell surface membrane protein. The company operates in the biopharmaceutical market, serving patients with autoimmune and inflammatory diseases. Lifordi's business model involves the discovery, development, and commercialization of novel therapeutics, supported by funding from prominent venture capital firms such as ARCH Venture Partners, 5AM Ventures, and Atlas Venture. Revenue is generated through partnerships, licensing agreements, and eventual product sales. The company's leadership team boasts extensive experience in drug development, immunology, and inflammatory diseases, positioning Lifordi as a leader in this specialized field.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Nov 2025 | $112M | $448M | Atlas Venture · ARCH Venture Partners · 5AM Ventures · Sanofi Ventures | ↗ |
Growth signals
Latest recorded traffic for Lifordi Immunotherapeutics is 300 monthly website visits, down 96.2% over the last three months. Lifordi Immunotherapeutics's team declined 4.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Lifordi Immunotherapeutics in the Boston ecosystem
The Lifordi Immunotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
Atlas Venture
ARCH Venture Partners
5AM Ventures
Sanofi Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lifordi Immunotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lifordi Immunotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









